Combination Improves Survival of Metastatic Melanoma Patients: Phase II Study

June 04, 2007 at 5:46 PM Cancer News
  •   Print
  •   Share
  •   Comments
  •  Text 
People who have been diagnosed with metastatic melanoma generally live between six and 12 months after diagnosis. Despite years of research, there are no long-term effective treatments and no cure.

In this study, researchers combined two chemotherapy drugs – paclitaxel (Taxol) and carboplatin – with bevacizumab, a drug that prevents the formation of new blood vessels and is used to treat cancer in combination with chemotherapy drugs.

The combination of paclitaxel (Taxol) and carboplatin has been beneficial in treating different cancers, such as metastatic lung cancer and ovarian cancer, Dr. Perez says.

Bevacizumab blocks the vascular endothelial growth factor (VEGF), a substance naturally produced in the body that stimulates the formation of new blood vessels, a process known as angiogenesis. This process is essential for tissue repair, such as wound healing, and for the overall the health of the body.

VEGF is also important for tumor growth, which depends to a large extent on the formation of new blood vessels to satisfy the increasing oxygen and nutritional needs of the growing tumor. Furthermore, there is evidence that overproduction of VEGF in response to chemotherapy may allow tumors to become more aggressive and resistant to the effects of chemotherapy by different mechanisms. Thus, it was thought that blocking VEGF with a drug like bevacizumab could facilitate the antitumor effects of chemotherapy in patients with metastatic melanoma.

Bevacizumab is a monoclonal antibody that binds VEGF and blocks its interaction with cellular receptors. This action prevents new blood vessels from forming and allows the chemotherapy to work.

Fifty-three patients were treated with carboplatin, weekly treatments of paclitaxel (Taxol) and biweekly bevacizumab. Researchers found that the treatment was well tolerated and prevented the tumor from spreading from eight to nearly 24 weeks.

The number of new melanoma cases has continued to rise at a rate of about 5 percent to 10 percent each year since the 1970s, Dr. Markovic says. Why" One cause, he says, is depletion of the ozone layer, but also, more cases are coming to light due to greater public awareness.

"The increase in incidence is a big worry, particularly when we still do not have an effective treatment. That's why this step, however small, is important," Dr. Markovic says.

Source-Eurekalert
LIN/M
Previous Page 2 Page 1 | 2 
 Email Email   RSS Feeds RSS Feeds   Print this page Print   Save this page Save   Link Link   Syndicate Syndicate   Comments Comments   Bookmark and Share
 
Comment & Contribute
Comments should be on the topic and should not be abusive. Comments are normally moderated and are reviewed after they are posted.
* Your comment can be maximum of 2500 characters

Notify me when reply is posted
I agree to the terms and conditions
  
If you have a question about health related issues, you can now post it in our Ask An Expert section on our community website Medwonders.com and get answers from our panel of experts.
X

Medwonders Health Network

  • Health News Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Archive
Date :
Category :
Keyword :
  • News Quick Links
News Central Health Watch
Latest Health News Health In Focus
News Category (500+) Breaking Health News
Popular News Celebrating Life
Health News and Press Release Medindia - Exclusive
News Photo Gallery India Special
News Video Gallery Lifestyle and Wellness
News From Other Resources
Melanoma
Complete Medindia Resources
News Categories:  
Women's Health Center

Cancer Related News

» Scientists Develop Compound That Triggers Cancer Cell Death » Iraqi National Hopes to Find Affordable Treatment for His Cancer in India
» New Technique can Help Doctors Detect Pancreatic Cancer » Colorectal Cancer Risk Factors Probed
» Breast MRI 'Better Than Clinical Approach for Predicting Chemotherapy's Efficiency' » No Need for PSA-Based Screening for Prostate Cancer: Task Force
» Blocking Protein Reduces Risk of Heart Damage After Chemo » Researchers Identify Early-life Risk Factors for Non-Hodgkin Lymphoma
Read More >>